Hemocellular Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
Hemocellular Therapeutics Inc. hopes to extend the life of donated human platelets with proprietary freeze-drying technology. Its Stasix, now in preclinical development, is a powdered form of platelets that can be stored at room temperature indefinitely. Once rehydrated, full functionality is restored immediately. Furthermore, Hemocellular claims that since it removes protein plasma before freeze-drying, no cross-matching to patients is necessary.
You may also be interested in...
Artificial Blood: Finding the Formula for Approval
Despite decades of effort and more than $1 billion dollars invested in commercial blood substitute R&D, no products are approved for use in the US. Can next-generation companies succeed where so many others have failed?
Gloucester Pharmaceuticals Inc.
Two subtypes of T-cell mediated lymphomas have been very difficult to treat using the existing cytotoxic chemotherapy treatments. CTCL and peripheral T-cell lymphoma (PTCL) patients receiving chemotherapy may experience severe, dose-limiting toxicities and develop resistance to the therapy. Gloucester Pharmaceuticals Inc. is developing a treatment that potentially is more effective than chemo, the company says, and the National Institutes of Health is backing its development.
Hemobiotech Inc.
Hemobiotech Inc. was formed to commercialize HBOC technology originally developed at Texas Tech University. By modifying hemoglobin with ATP, glutathione and adenosine, the company claims it eliminates toxicity and vasoactivity. The company also has evidence that HemoTech may have the added benefit of inducing erythropoiesis.